Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
Last trade$70.69
Day change+$1.47 (+2.12%)
Day range$67.74 – $71.63
Volume534,871
Market cap$7.48B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$7.48B
Price / earnings
46.21×
Price / book
8.97×
Price / sales
7.76×
EV / sales
7.66×
EV / EBITDA
64.95×
Profitability
Earnings per share
$1.50
Return on assets
15.66%
Return on equity
19.42%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
3×
Quick ratio
2.94×
Cash ratio
0.56×
Cash flow
Price / cash flow
37.77×
Price / free cash flow
38.45×
Free cash flow
$194.62M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CORT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$340.47M
$256.15M
$164.9M
$202.13M
$207.64M
$194.43M
$157.21M
$181.89M
Cost of revenue
$4.61M
$4.06M
$2.88M
$2.55M
$4.6M
$3.43M
$2.4M
$2.96M
Gross profit
$335.86M
$252.09M
$162.02M
$199.58M
$203.04M
$191M
$154.81M
$178.93M
Selling, general and administrative
$164.43M
$156.9M
$145.36M
$130.24M
$123.98M
$103.85M
$90.66M
$83.37M
Research and development
$56.71M
$53.89M
$66.27M
$64.86M
$68.85M
$60.47M
$60.74M
$70.3M
Total operating expenses
$221.14M
$210.79M
$211.62M
$195.09M
$192.82M
$164.32M
$151.4M
$153.67M
Operating income
$114.72M
$41.3M
-$49.6M
$4.49M
$10.22M
$26.68M
$3.42M
$25.26M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
$120.31M
$45.93M
-$44.72M
$9.91M
$15.24M
$31.69M
$9.62M
$31.96M
Income taxes
-$6.47M
$2.94M
-$12.95M
-$14.38M
-$4.43M
-$3.46M
-$10.93M
$1.21M
Net income
$126.78M
$42.99M
-$31.76M
$24.29M
$19.67M
$35.15M
$20.55M
$30.75M
Net income attributable to common shareholders
$126.78M
$42.99M
-$31.76M
$23.9M
$19.67M
$35.15M
$20.55M
$30.39M
EBITDA
$115.75M
$42.16M
-$49M
$4.78M
$10.7M
$27.14M
$3.88M
$25.54M
Basic earnings per share
$1.17
$0.40
-$0.30
$0.23
$0.19
$0.33
$0.19
$0.29
Diluted earnings per share
$1.01
$0.36
-$0.30
$0.20
$0.16
$0.29
$0.17
$0.26
Recent news
Company coverage with links to the original publishers.
Corcept Therapeutics reported Q3 2026 earnings of $1.01 per share, beating consensus estimates of $0.68 per share, with a 48.53% earnings surprise. Revenues reached $340.47 million, surpassing estimates by 3.43% compared to $207.64 million year-ago. The stock has gained 131.2% year-to-date. However, the company holds a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.
Corcept Therapeutics reported Korlym sales of $373.5 million in H1 2026, up 6.2% year-over-year. The FDA approval of Lifyorli (relacorilant) in March 2026 generated $47.6 million in Q2 2026, marking the company's first quarter of commercial availability. The new drug aims to reduce CORT's dependence on Korlym. Relacorilant is also being studied in combination with other therapies for various cancers, with an FDA decision on the Cushing's syndrome indication expected by December 2026.
Zacks highlights five non-tech Nasdaq stocks with Zacks Rank #1 (Strong Buy) ratings positioned for Q4 gains. Ross Stores benefits from strong sales momentum and store expansion; Roku capitalizes on the shift from linear TV to streaming advertising; APA Corp offers favorable capital efficiency and long-term growth; Corcept Therapeutics sees strong demand for Korlym and new product launches; Halozyme benefits from collaboration royalties and milestone payments.
Despite the Nasdaq's tech-heavy composition, five non-tech Nasdaq-listed stocks with Zacks Rank #1 ratings are positioned for strong growth. Ross Stores plans 115 store openings with 13% Q2 sales growth, Roku's advertising revenue climbed 24.8%, APA Corp benefits from cost savings and long-term growth projects, Corcept Therapeutics sees strong drug demand with recent FDA approvals, and Halozyme generates royalties from pharma collaborations.
With September CPI rising 3.7% year-over-year and inflation concerns potentially triggering additional Fed rate hikes, the article recommends three low-beta defensive healthcare stocks: Cardinal Health (CAH), UnitedHealth Group (UNH), and Corcept Therapeutics (CORT). These stocks offer lower market volatility and strong earnings growth prospects in an uncertain economic environment.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.